Targacept, Inc. was founded in 1997 and is based in Winston-Salem, North Carolina. Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of neuronal nicotinic receptors (NNR) Therapeutics for the treatment of multiple diseases and disorders of the central nervous system. The Company has clinical-stage product candidates for target indications in three therapeutic areas, which includes cognitive impairment, depression and anxiety, and pain. It also has preclinical programs focused in smoking cessation, addiction, obesity, pain, Parkinson’s disease and inflammation. The Company has collaboration with AstraZeneca and an alliance with GlaxoSmithKline. The drug discovery activities utilize computer-based molecular design methodologies and biological data for a library of compounds developed and collected over more than 20 years. The technologies are referred to as Pentad. The Company use Pentad to design or optimize AZD3480 (TC-1734), TC-5619, TC-2216 and TC-6499.

Goldshield Group plc, through its subsidiaries, engages in the development, marketing, and distribution of pharmaceutical and consumer health products. It offers ethical pharmaceuticals, non-prescription medicines, vitamins, minerals and supplements, and various other healthcare products. The company’s pharmaceutical products comprise Ostex, a glucosamine sulphate for joints; Flexeze for glucosamine; and Flexeze Truefil capsules for joints and connective tissues. Its pharmaceutical products are used for chronic disease areas, including cardiovascular diseases, central nervous system disorders, and musculoskeletal conditions. The company’s consumer health products include Appesat for natural weight loss; LIPObind, a natural weight management supplement; Lubramine, a supplement for joint health; Kamillosan, a breastfeeding product; and Infaderm, a soap-free bubble bath product. Its consumer health products also include joints and mobility, bone health, antioxidants, heart and circulation, digestion and detox, weight management, men’s health, women's health, skin care and beauty, heart and bone health, fitness nutrition, immune boosters, joint health, cardiac health, multi vitamins, pet health, centural specials, anti aging, eye health, and well being products. In addition, the company develops wellbeing villages and resorts; publishes magazines for consumers, as well as sells subscriptions and advertising space; and provides telemarketing and management services. Goldshield Group operates in the United Kingdom, Ireland, North America, and India. The company was founded in 1991 and is headquartered in Croydon, the United Kingdom. As of December 21, 2009, Goldshield Group plc was taken private.

AMAG Pharmaceuticals, Inc. company was founded in 1981 and is based in Lexington, Massachusetts. AMAG Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic iron compounds to treat anemia in the United States, Europe, and Japan. It also provides novel imaging agents to aid in the diagnosis of cancer and cardiovascular diseases. It offers Feraheme, an iron replacement therapeutic agent for the treatment of iron deficiency anemia and used as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease; and GastroMARK used for delineating the bowel in MRI. AMAG Pharmaceuticals products also include Combidex, an investigational functional molecular imaging agent.

Neogen Corporation was founded in 1981 and is based in Lansing, Michigan. Neogen Corporation (Neogen), together with its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety. The Company operates in two primary business areas: the food safety segment and the animal safety segment. The Company’s food safety segment consists primarily of diagnostic test kits and complementary products marketed by sales personnel in the North American, Mexico, the United Kingdom and other parts of Europe, and by distributors elsewhere to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed. Neogen’s animal safety segment is engaged in the development, manufacture and marketing of pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals and diagnostic products for the worldwide animal safety market. In May 4, 2009, Neogen acquired International Diagnostic Systems Corporation.

China Shenghuo Pharmaceutical Holdings, Inc. (Shenghuo) is primarily engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products. Almost all of its products are derived from the medicinal herb Panax notoginseng, also known as Sanqi, Sanchi or Tienchi. Its main product, Xuesaitong Soft Capsules, accounted for more than 87% of its sales for the year ended December 31, 2008. Xuesaitong Soft Capsules are primarily sold in China, but the product is also sold in various developing countries, including Malaysia, Indonesia and Kyrgyzstan. Panax notoginseng saponins (PNS), the active ingredient in Panax notoginseng, is extracted from the plant using high-tech equipment and in accord with Good Manufacturing Practice (GMP) standards.

PacificHealth Laboratories, Inc. company was founded in 1995 and is based in Matawan, New Jersey. PacificHealth Laboratories, Inc. engages in the development, marketing, and sale of protein-based nutritional products for appetite regulation. It principally focuses on sports performance, weight loss, and management of Type II diabetes. The company offers ENDUROX R4, a recovery drink; ACCELERADE, a sports drink; ACCEL GEL, an energy gel; and ENDUROX EXCEL, a dietary supplement. PacificHealth Laboratories sells its products through retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Merz may be a little sterile, but it aims to take care of every part of the functioning human organism. Merz primarily makes pharmaceuticals, focusing on therapies for central nervous system and liver metabolism. The company also offers several OTC products, including cold remedies, skin care products, and vitamin supplements under the brand names tetesept and Merz Special. Subsidiaries include Merz Pharmaceuticals, Merz Consumer Care, Merz Dental, maker of dental equipment and artificial teeth, and Merz & Krell, which produces Senator-brand writing instruments.

Bilcare, Inc., formerly ProClinical Pharmaceutical Services, is in favor of pharma. Bilcare, Inc. company, which also operates as Bilcare Global Clinical Services, is the American arm of parent company Bilcare Ltd. Its aim is to help pharmaceutical companies prepare for and conduct clinical trials. Bilcare's offerings include a wide range of analytical research, formulation development, manufacturing, and packaging and labeling of clinical supplies. Logistics services include the storage, distribution, reconciliation, and destruction of clinical trial supplies and investigational medicines. Its services encompass all levels of pharmaceutical drug trials.

Ash Stevens, Inc. was founded in 1962 to provide chemical research for the government and later branched out into the private sector. Ash Stevens, Inc. company, a contract pharmaceutical manufacturer develops and manufactures active pharmaceutical ingredients (APIs) for other pharmaceutical companies. It also supports clinical drug trials and helps others navigate the FDA's regulatory maze. Its customers include the federal government and commercial pharmaceutical firms. The company's portfolio includes about a dozen FDA-approved drug components.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.